Skip to main content

Table 2 Factors associated with Mortality (N = 13) in COVID-19 population

From: A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases

 

Unadjusted

Adjusted

RR

95% CI

p value

RR

95% CI

p value

Age

1.053

1.012, 1.096

0.071

1.037

0.996, 1.079

0.079

Gender M:F

1.357

0.456, 4.044

0. 583

   

RA

1.475

0.487, 4.465

0.492

   

SLE

0.659

0.088, 4.955

0.685

   

Duration of AIRD (months)

 1–24

1

     

 25–48

1.606

0.534, 4.835

0.399

   

 > 48

0.393

0.048, 3.201

0.383

   

Diabetes Mellitus

3.471

1.209, 9.960

0.021

1.623

0.519, 5.104

0.403

Hypertension

2.233

0.755, 6.607

0.146

   

Pre-existing Lung involvement

6.362

2.231, 18.130

0.001

4.315

1.416, 13.150

0.010

Current Steroid use

2.23

0.87–5.71

0.09

   

HCQ

0.341

0.096, 1.215

0.097

   

CYC

2.41

0.36, 16.1

0.362

   

MMF

1.689

0.511, 5.57

0.390

   

Rituximab

1.72

0.25, 11.8

0.581

   

ACEi/ARB

1.259

0.290, 5.468

0.759

   

Smokers

6.162

1.593, 23.83

0.008

   
  1. Unadjusted and adjusted relative risk and 95% confidence interval using bivariate and multivariate log binomial regression analysis; Multivariate model using stepwise method—variables entered in to the model were age, gender, presence of diabetes mellitus, pre existing lung involvement, current steroid use and current HCQ use
  2. AIRD autoimmune rheumatic diseases, RA rheumatoid arthritis, SLE systemic lupus erythematosus, HCQ hydroxychloroquine, CYC cyclophosphamide, MMF mycophenolate mofetil, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us